ReviewVirchows Archiv : an international journal of pathology2014
Tissue prognostic biomarkers in primary cutaneous melanoma.
Review in Virchows Archiv : an international journal of pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 50 citations in OpenAlex.
- Liquid Biopsy for Cutaneous Melanoma: Opportunities and Challenges in Detecting and Characterizing Circulating Tumor Cells.Journal of dermato-oncology · 2025Article
- Effects of BRAF V600E and NRAS mutational status on the progression-free survival and clinicopathological characteristics of patients with melanoma.Oncology letters · 2023Article
- Health professional and patient views of a novel prognostic test for melanoma: A theoretically informed qualitative study.PloS one · 2022Article
- Addressing the importance of melanoma tumor-infiltrating lymphocytes in disease progression and clinicopathological characteristics.Molecular and clinical oncology · 2021Article
- Clinical Significance of Tumor Microenvironment in Acral Melanoma: A Large Single-Institution Study of Caucasians.Journal of clinical medicine · 2021Article
- Digital Immunophenotyping Predicts Disease Free and Overall Survival in Early Stage Melanoma Patients.Cells · 2021Article
- Timing of sentinel node biopsy independently predicts disease-free and overall survival in clinical stage I-II melanoma patients: A multicentre study of the Italian Melanoma Intergroup (IMI).European journal of cancer (Oxford, England : 1990) · 2020Article
- Biomarkers Predictive of Survival and Response to Immune Checkpoint Inhibitors in Melanoma.American journal of clinical dermatology · 2020Review
- Elevated Neutrophil-to-Lymphocyte Ratio Is Associated With Poor Outcomes for Melanoma Patients Treated With PD-1 Inhibitor or Chemotherapy in a Chinese Population.Frontiers in oncology · 2020Article
- Epidermal autophagy and beclin 1 regulator 1 and loricrin: a paradigm shift in the prognostication and stratification of the American Joint Committee on Cancer stage I melanomas.The British journal of dermatology · 2020Article
- Elevated nuclear auto-antigenic sperm protein promotes melanoma progression by inducing cell proliferation.OncoTargets and therapy · 2019Article
- Cofilin-1 levels and intracellular localization are associated with melanoma prognosis in a cohort of patients.Oncotarget · 2018Article
- Using global gene expression to discriminate thin melanomas with poor outcomes.Molecular & cellular oncology · 2017Article
- 5-Hydroxymethylcytosine is an independent predictor of survival in malignant melanoma.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2017Article
- Skewed Differentiation of Circulating Vγ9Vδ2 T Lymphocytes in Melanoma and Impact on Clinical Outcome.PloS one · 2016Article
- Article
- Improving Melanoma Path Reports: the Importance of Histopathological Parameters in Diagnosis of Cutaneous Melanoma.Maedica · 2015Article
- Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR.Nature medicine · 2015Article
- Loss of primary cilia in melanoma cells is likely independent of proliferation and cell cycle progression.The Journal of investigative dermatology · 2015Article
- Prognostic biomarkers: an introduction.Virchows Archiv : an international journal of pathology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cutaneous melanoma (CM) causes the greatest number of skin cancer-related deaths worldwide. Predicting CM prognosis is important to determine the need for further investigation, counseling of patients, to guide appropriate management (particularly the need for postoperative adjuvant therapy), and for assignment of risk status in groups of patients entering clinical trials. Since recurrence rate is largely independent from stages defined by morphological and morphometric criteria, there is a strong need for identification of additional robust prognostic factors to support decision-making processes. Most data on prognostic biomarkers in melanoma have been evaluated in tumor tissue samples by conventional morphology and immunohistochemistry (IHC) as well as DNA and RNA analyses. In the present review, we critically summarize main high-quality studies investigating IHC-based protein biomarkers of melanoma outcome according to Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)-derived criteria. Pathways have been classified and conveyed in the "biologic road" previously described by Hanahan and Weinberg. Data derived from genomic and transcriptomic technologies have been critically reviewed to better understand if any of investigated proteins or gene signatures should be incorporated into clinical practice or still remain a field of melanoma research. Despite a wide body of research, no molecular prognostic biomarker has yet been translated into clinical practice. Conventional tissue biomarkers, such as Breslow thickness, ulceration, mitotic rate and lymph node positivity, remain the backbone prognostic indicators in melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.